NCT02955160 is a Phase 1 clinical trial of Multivalent in Pneumococcal Infections, sponsored by Pfizer.

Who is sponsoring NCT02955160?

NCT02955160 is sponsored by Pfizer.

What drugs are being tested in NCT02955160?

Interventions in NCT02955160: Multivalent, Tdap.

What condition does NCT02955160 study?

NCT02955160 studies Pneumococcal Infections.

Is NCT02955160 still recruiting?

NCT02955160 is currently completed. Last updated 11 September 2018.

Last reviewed 2018-09-11 · How we verify

NCT02955160

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years

Completed Phase 1 Last updated 11 September 2018

What this trial tests

Phase 1 trial testing Multivalent in Pneumococcal Infections in 66 participants. Completed in 1 August 2017.

Timeline

3 November 2016

Primary endpoint
1 August 2017

1 August 2017

Quick facts

Lead sponsor	Pfizer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	66
Start date	3 November 2016
Primary completion	1 August 2017
Estimated completion	1 August 2017
Sites	1 location across United States

Drugs / interventions tested

Multivalent — full drug profile →
Tdap — full drug profile →

Conditions studied

Pneumococcal Infections — all drugs for Pneumococcal Infections →

Sponsor

Pfizer — full company profile →

Who can join

Adults 18 to 49, any sex, with Pneumococcal Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1 first-in-human, randomized, controlled, observer-blinded study with a 2-arm parallel design. Healthy adults aged 18 to 49 years of age with no history of pneumococcal vaccination will be randomized equally to receive either a single intramuscular dose of multivalent pneumococcal conjugate vaccine or a licensed tetanus, diphtheria, acellular pertussis combination vaccine (Tdap) (control group).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Multivalent

Trials testing the same drug.

NCT03550313 — Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy I · Phase 2 · terminated
NCT03512288 — Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants · Phase 2 · completed
NCT03313050 — A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age · Phase 2 · completed
NCT03313037 — Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 · Phase 2 · completed

Other recruiting trials for Pneumococcal Infections

Currently open trials in the same condition.

NCT06822907 — Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults · Phase 4 · recruiting
NCT07017777 — A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infant · Phase 3 · recruiting
NCT06838000 — Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) i · Phase 3 · active not recruiting
NCT06608199 — A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 · Phase 3 · recruiting
NCT04945681 — Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People · Phase 4 · active not recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02955160 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 11 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02955160.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing